Is the Time Ripe to Buy Johnson & Johnson Stock?

If you owned Johnson & Johnson (NYSE: JNJ  ) stock at the beginning of 2013, you're sitting atop gains of more than 20% right now. If you didn't own shares of J&J, you might be wishing that you did. Is the time still ripe to buy -- or has the train left the station? Let's take a look.

Taking a breather
After a stellar start in 2013, Johnson & Johnson has taken a little breather since late May. Shares have pulled back slightly.

JNJ Chart

JNJ data by YCharts.

I actually view this as a good development. The S&P 500 index also pulled back during the same period, but Johnson & Johnson shares retreated by less than half as much as the broader index. This reflects solid investor support for the stock.

It's been a while since J&J enjoyed such a nice run. The company has encountered some rough spots over the last few years, particularly with product recalls and litigation woes. These issues even resulted in Warren Buffett dumping much of his stake, saying that Johnson & Johnson had made "too many mistakes."

Relatively speaking
Of course, J&J hasn't been alone in climbing this year. Many blue chips have performed well in 2013 thus far. Among its peers, though, Johnson & Johnson stock looks to be one of the biggest winners.

Fellow pharmaceutical giant Pfizer (NYSE: PFE  ) saw its shares jump more than 20% by April. However, the stock has fallen quite a bit since then. Shares are now only up less than 13%.

Similarly, Merck (NYSE: MRK  ) was up more than 20% for the year in early June. The stock now claims year-to-date gains of 14%.

Although its quite smaller in terms of market cap, Abbott Labs (NYSE: ABT  ) has a business model closer to that of Johnson & Johnson than most other pharmaceutical firms. Abbott shares followed a similar path as Merck -- up more than 20% before falling. The stock is now up around 14% for the year.

Since J&J didn't pull back as much as some of its peers, is it now much pricier as a result? Not necessarily.

Its trailing price-to-earnings multiple of below 24 stands very close to that of Merck. Pfizer and Abbott have significantly lower trailing P/E values of less than 14 and 11, respectively. However, looking ahead paints a different picture.

Abbott's forward P/E of almost 16 ranks as the highest of the four companies. J&J trails with a forward P/E a little under 15. Meanwhile, Pfizer and Merck both have forward multiples between 12 and 13. Factoring in these expectations of future earnings makes Johnson & Johnson stock look reasonably priced in comparison with the other stocks.

Wonderful
For investors looking at the long run, Johnson & Johnson is nearly always worth consideration. Just as Warren Buffett said when discussing the company's mistakes in recent years, J&J has "a lot of wonderful products and it's got a wonderful balance sheet."

I'd throw in a wonderful dividend yield to that mix. J&J's yield currently stands at 3.2%. Is the time ripe to buy Johnson & Johnson stock? The signs point to it being a wonderful time.

Speaking of wonderful dividends, The Motley Fool has compiled a special free report outlining our nine top dependable dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost! Just click here.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2515624, ~/Articles/ArticleHandler.aspx, 7/25/2014 8:36:09 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement